# A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

> **NCT04514159** · PHASE1 · COMPLETED · sponsor: **Zeno Alpha Inc.** · enrollment: 14 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ZN-c5
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04514159
- **Lead sponsor:** Zeno Alpha Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2022-10-24
- **Final completion:** 2022-10-24
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04514159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04514159, "A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04514159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*